Evorpacept

Drug Overview

Evorpacept is an advanced, high-tech biological medicine used in the modern fight against cancer. It is not a traditional chemotherapy that kills cells directly. Instead, it is a “Smart Drug” classified as a next-generation immunotherapy. It is designed to disable the “shields” that cancer cells use to hide from the body’s natural defense system.

Here are the key details about this agent:

• Generic Name: Evorpacept (also known by the research code ALX148).
• US Brand Names: None yet. It is currently an investigational drug.
• Drug Class: CD47 Blocker / Myeloid Checkpoint Inhibitor.
• Route of Administration: Intravenous (IV) infusion.
• FDA Approval Status: Currently investigational. It has received Fast Track and Orphan Drug designations for certain cancers but is not yet approved for general public use outside of clinical trials.

What Is It and How Does It Work? (Mechanism of Action)

To understand how evorpacept works, it helps to think of the immune system as a security team. One of the most important members of this team is a cell called a macrophage. The macrophage’s job is to “eat” and destroy harmful cells, including cancer.

The “Don’t Eat Me” Signal

Cancer cells are very clever. They display a protein on their surface called CD47. This protein acts like a “Don’t Eat Me” signal. When a macrophage approaches a cancer cell, the CD47 protein binds to a receptor on the macrophage called SIRP-alpha. This connection sends a signal to the immune cell to stop and leave the cancer cell alone.

How Evorpacept Breaks the Shield

Evorpacept is a modified protein designed to block this interaction at the molecular level:

• High-Affinity Binding: Evorpacept is engineered to be much “stickier” than the natural proteins in the body. It latches onto the CD47 protein on the cancer cell surface.
• Blocking the Connection: By covering the CD47 protein, evorpacept prevents it from touching the SIRP-alpha receptor on the macrophage.
• Activating the Immune System: Once the “Don’t Eat Me” signal is blocked, the macrophage can finally see the cancer cell as a threat and begin to destroy it.
• Designed for Safety: Unlike older CD47 blockers, evorpacept is designed with an “inactive” tail (Fc region). This means it blocks the shield on cancer cells without accidentally sticking to and damaging healthy red blood cells, which helps avoid severe anemia.

FDA Approved Clinical Indications

Because evorpacept is currently in the investigational phase, it does not yet have official FDA-approved indications for routine hospital use. However, it is being tested in advanced clinical trials for the following:

Oncological Uses (In Clinical Trials):

• Gastric and Gastroesophageal Junction Cancer: Often used in combination with other drugs like trastuzumab.
• Head and Neck Squamous Cell Carcinoma: Being studied alongside immunotherapy drugs like pembrolizumab.
• Non-Small Cell Lung Cancer (NSCLC): Used to see if it can make standard treatments work better.
• B-cell Non-Hodgkin Lymphoma: Investigated for use with rituximab.

Non-oncological Uses:

• There are currently no non-oncological uses for this drug.

Dosage and Administration Protocols

Evorpacept is given as a liquid through a needle into a vein. Because it is used in clinical trials, the exact dose is carefully managed by a team of specialist doctors.

Clinical Efficacy and Research Results

Recent clinical studies conducted between 2020 and 2025 highlight the potential of evorpacept when used as a “force multiplier” for other treatments.

• ASPEN-01 Trial Results: In studies for gastric cancer, evorpacept was combined with standard targeted therapy. Early data showed an Objective Response Rate (ORR) of approximately 52% in certain groups, which is a significant improvement over standard therapy alone.
• Disease Progression: In patients with head and neck cancer who had previously failed other treatments, adding evorpacept helped stabilize the disease or shrink tumors in a higher percentage of patients compared to those not receiving the drug.
• Survival Data: While long-term survival rates are still being collected, current research indicates that the “Progression-Free Survival” (the time a patient lives without the cancer getting worse) is improved when evorpacept is added to existing immunotherapy regimens.

Safety Profile and Side Effects

One of the main goals in developing evorpacept was to make it safer than earlier immune checkpoint inhibitors. However, because it activates the immune system, side effects can still occur.

Black Box Warning:

• There is no FDA Black Box Warning for this investigational agent.

Common Side Effects (>10%):

• Fatigue: Feeling very tired or lacking energy.
• Infusion Reactions: Fever, chills, or dizziness during the injection.
• Nausea: Mild stomach upset.
• Headache: Usually manageable with standard over-the-counter medicine.

Serious Adverse Events:

• Cytopenia: A drop in blood cell counts (white cells, red cells, or platelets).
• Immune-Related Issues: Because the drug “wakes up” the immune system, the body may occasionally attack healthy organs like the skin, liver, or colon.

Management Strategies:

• Pre-medication: Patients may be given Tylenol or antihistamines before the infusion to prevent reactions.
• Monitoring: Regular blood tests are performed to check for any signs of anemia or organ stress.
• Steroids: If the immune system becomes overactive, doctors use steroid medications to calm it down

Research Areas

Evorpacept is a major part of research into Combination Immunotherapy. Doctors are finding that while evorpacept is good on its own, it is “better with friends.” Scientists are looking at how it can be used with Stem Cell research to help the bone marrow create more effective immune cells. By clearing the “CD47 shield” from cancer cells, researchers believe they can help new stem-cell-derived immune treatments find and kill tumors much faster.

Patient Management and Practical Recommendations

To ensure the best results and highest safety, patients should follow specific guidelines.

Pre-treatment Tests to be Performed:

• Blood Typing: Even though evorpacept is safer for red blood cells, doctors still perform a baseline blood type and screen.
• Complete Blood Count (CBC): To ensure white and red blood cells are at healthy levels.
• Liver Function Tests: To check how the body is processing medications.

Precautions During Treatment:

• Watch for Fever: Tell your doctor immediately if you develop a fever or chills, as this can be a sign of an immune reaction or infection.
• Lying Still: You must lie or sit comfortably during the infusion to ensure the IV line stays in place.

“Do’s and Don’ts” List:

• DO drink plenty of water before your appointment to make the IV placement easier.
• DO report any new skin rashes or diarrhea to your medical team right away.
• DON’T miss your scheduled blood test appointments; these are vital for catching side effects early.
• DON’T start any new supplements or vitamins without asking your oncologist first.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. Evorpacept is an investigational agent and is not currently approved by the US Food and Drug Administration (FDA) for general clinical use. It is available only through participation in approved clinical trials. Always consult with a qualified healthcare professional or your treating oncologist regarding diagnosis, treatment options, and eligibility for clinical trials.